ClinicalapplicationoflowmolecularweightheparindrugsPapertowritethenetwork:Author:GaobuiltautumnRenzengYong,ZhangXiangning[Keywords:]lowmolecularweight[KeyWords]lowmolecularweightheparin,heartdisease,cerebralinfarction,colitis,diabeticnephropathyAlowmolecularweightheparinroleLowmolecularweightheparin(LMWH)isthesmallermolecularweightfragmentsisolatedfromstandardheparin,anditsfunction:theanti-FXaactivitywassignificantlyhigherthantheactivityofanti-Fa,aslightanticoagulantactivity(anti-factorⅡactivitylessthan45IU/mg)longhalf-life,isnotobvioustoextendKPTTbleedingsideeffects;promotefibrinolysis,andvascularendothelialcellstoreleaseplasminogenactivatorandshortentheeuglobulinlysistime,sostrongantithromboticeffect,enhancedanti-vascularendothelialcellsantithromboticeffectswithoutinterferencewiththevascularendothelialcells,andthereforenosignificanteffectonbleedingandplateletfunction,haveneuroprotectiveeffects[1].12clinicalapplication2.1Thetreatmentofcoronaryatheroscleroticheartdisease(CHD)Tissuefactor(TF)isawidelypresentinavarietyofcellplasmamembraneglycoprotein,theextrinsiccoagulationsysteminitiationfactorandtissuefactorpathwayinhibitor(TFPI)ispresentinthebloodundernormalphysiologicalconditionsofnaturalanticondensedsubstanceshasanimportantroleintheregulationofthecoagulationsysteminvivo.Chenin[2]usingenzyme-linkedimmunosorbentassayin22patientswithstableangina(SA),20patientswithunstableangina(UA)and18casesofacutemyocardialinfarction(AMI)patients,determinationofitsresultsCHDpatientswithlowmolecularweightheparintherapybeforeTFandTFPIcomparedwithhealthycontrolgroupsignificantlywithincreased,ofTFPI/theTFratiothanthehealthycontrolgroupwassignificantlyloweraftertreatmentbeforetheTFcomparedwithtreatmentsignificantlywithdeclineofTFPI/TFratiowassignificantlyhigherthanbeforetreatment,whileTFPIwassignificantlyhigher.studieshaveshownthatCHDexistenceofthehyperactivityof2thecoagulation,TFplaysaroleincoronarythrombosis,lowmolecularweightheparincanreducethelevelofTF,TFPIanewanticoagulant,lowmolecularweightheparincanenhanceitsrole.2.2acutecoronarysyndromeinvolvedinthepre-treatmentToexplorenon-ST-segmentelevationacutecoronarysyndrome(coronary)toacceptthesafetyandefficacyofpercutaneouscoronaryinterventionbeforeenoxaparin,accordingtoHuDayi,etc.[3]reportedthat507casesofacutecrownveinsyndromepatientswithoralaspirinafteradmissiongivenenoxaparin1mg/kgsubcutaneously,1/12h,atleastfor48h,untiltheinterventiontreatmentthesamedaymorning.expertsinvolvedin8hafterthelastinjectionexaminationortreatment.intraoperative/postoperativeadditionalheparinorlowmolecularweightheparinisnolongertheresultof176cases(93.2%)patientswithanti-factorXaactivity>0.5IU/mL.Within30doffollow-up,acutemyocardialinfarctionin16cases(3.2%),recurrentunstableanginain34cases(6.7%),1case(0.2%)revascularizationand1patientdied(lreferstointestinal3perforation).minorbleedingin24casesaccountedfor4.7%.30dfollow-upoflpatientshadnon-Q-wavemyocardialinfarction,patientswithunstableangina.resultsshowthathigh-riskacutecoronarysyndromepatientssubcutaneousinjectionofenoxaparinatleast48h,thelastinjectionoftheexpertsinvolvedinexaminationortreatmentfor8h,nolongertotheanticoagulantagentsonpatientsafety.2.3ThetreatmentofseverecerebralinfarctionAcutecerebralinfarctionisahighincidenceandhighmorbidity,highmortality,anticoagulationisaneffectivemethodforthetreatmentofacute...